Tongyi Pharmaceuticals announced that it has entered into an exclusive licensing agreement with MultiValent Biotherapies for CBP-1018, a peptide-drug conjugate for the treatment of prostate cancer

CAR-T Digest - August 2020

Weekly Digest - December 2025

22 December 2025: Tongyi Pharmaceuticals announced that it has entered into an exclusive licensing agreement with MultiValent Biotherapies for CBP-1018, a peptide-drug conjugate for the treatment of prostate cancer

Tongyi Pharmaceuticals entered an exclusive licensing agreement with MultiValent Biotherapies for CBP-1018, a peptide–drug conjugate for prostate cancer, granting MultiValent rights outside greater China
Tongyi will receive a US$20 million upfront payment, a 20% equity stake in MultiValent, eligibility for up to ~US$2 billion in development, regulatory, and commercial milestones, plus tiered royalties
CBP-1018 is built on Tongyi’s proprietary Bi-XDC (bispecific dual-ligand conjugate) platform and links Auristatin-E to a bispecific peptide targeting PSMA and FRα, both highly expressed in prostate cancer
In a Phase 1/2 trial of over 110 patients with metastatic castration-resistant prostate cancer, intravenous CBP-1018 showed encouraging safety and efficacy, achieving a median progression-free survival of 8.5 months, comparable to the approved PSMA-targeted radioligand therapy
MultiValent plans to develop CBP-1018 as a focal therapy, with preclinical data indicating that local (topical) administration increases prostate tissue exposure while reducing systemic toxicity, potentially offering an alternative to radiation, surgery, or androgen deprivation therapy